Zilico
Real-time cervical cancer diagnostic system using EIS.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Growth Equity VC | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 75 % | (2 %) | (67 %) | 149 % | (73 %) | 79 % | (6 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (850 %) | (1336 %) | (5453 %) | (1105 %) | (4570 %) | (2996 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1019 %) | (1469 %) | (5682 %) | (1216 %) | (4480 %) | (3095 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 64 % | 65 % | 585 % | - | - | - | - |
Source: Company filings or news article, Dealroom estimates
Related Content
Zilico is a medical diagnostics company, founded in 2006, that specializes in designing and manufacturing devices for the real-time diagnosis of various cancers. The company was established following a collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust in the UK. The founders recognized that the existing methods for cervical cancer diagnosis were slow and sometimes inaccurate, and they aimed to create a more effective solution.
Zilico's flagship product is ZedScan, a portable, handheld diagnostic system used as an adjunct to colposcopy for a more objective and accurate assessment of cervical tissue. The device utilizes a patented technology called Electrical Impedance Spectroscopy (EIS), which measures the electrical properties of tissues to differentiate between normal, pre-cancerous (cervical intraepithelial neoplasia or CIN), and cancerous cells in real-time. This non-optical diagnostic tool provides immediate results, enhancing the accuracy of CIN detection, particularly in cases referred with low-grade abnormalities. The ZedScan system includes a handset, a docking station for charging and data transfer, and single-use sensors for each patient examination.
The company's business model involves selling the ZedScan system to hospitals and clinics, which then use the device to improve their cervical cancer screening programs. By providing a more accurate diagnosis at the first visit, ZedScan helps clinicians make better-informed treatment decisions, reduce the number of biopsies, and minimize patient anxiety. The technology is used in several NHS trusts in the UK and in hospitals across Europe. Zilico is also exploring the application of its EIS platform technology for detecting other cancers, such as oral cancer.
Keywords: Electrical Impedance Spectroscopy, EIS, cervical cancer diagnostics, ZedScan, colposcopy adjunct, real-time diagnostics, medical devices, MedTech, CIN detection, non-optical diagnosis, cancer screening, Sheffield University spin-out, diagnostic equipment, women's health, pre-cancerous detection, gynecology, medical technology, Sameer Kothari, John Tidy, healthcare technology